WAVE Life Story

WAVE Life Sciences Ltd -- USA Stock  

USD 38.85  2.05  5.57%

Macroaxis does not monitor all media channels or aggregates social signals for WAVE Life. But even though we do not provide professional-grade financial sentiment analysis on WAVE Life Sciences, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for WAVE Life. See also WAVE Life Hype Analysis, WAVE Life Correlation and WAVE Life Performance
WAVE Life exotic insider transaction detected
Filed transaction by Wave Life Sciences Ltd director. Unconventional Insider trading

WAVE Life Sciences Ltd insider trading alert for general transaction of series b preferred shares by Ken Takanashi, the corporate stakeholder, on October 6, 2017. This event was filed by Wave Life Sciences Ltd with SEC on 2015-11-10. Initial filing of beneficial ownership - SEC Form 3. Ken Takanashi is currently serves as corporate secretary and director of WAVE Life Sciences

Story Momentum

This article from MacroaxisInsider published on 06 of October contributed to the next trading period closing price depreciation.The trading price change to the next next day price was 4.6% . The trading price change when the story was published to current price is 47% .

Similar stores for WAVE Life

a day ago at http://www.nasdaq.com 
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented ...
nasdaq News
CAMBRIDGE, Mass., Dec. 11, 2017 -- Wave Life Sciences Ltd. , a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced data from ... WAVE LIFE SCIENCES LTD. Files An 8-K Regulation FD Disclosure - Market Exclusive Chandra Vargeese Sells 1500 Shares of Wave Life Sciences Ltd Stock - The Ledger Gazette
over two weeks ago at http://ledgergazette.com 
WAVE Life Sciences Ltd. Rating Increased to Hold at BidaskClub
news
The Ledger GazetteRedmile Group, Llc is the second biggest holder of WAVE Life Sciences Ltd. Post AnalystInsider Buying WAVE Life Sciences Ltd. Director Purchases 423398 Shares of Stock Dispatch TribunalFull coverage
over a month ago at http://thestocktalker.com 
Trading Wire Consensus Projections on Shares of WAVE Life Sciences Ltd ...
news
Sell-side analysts are projecting that WAVE Life Sciences Ltd. will report a current quarter EPS of -0.94 when the company issues their next quarterly report.

Did you try this?

Run Portfolio Diagnostics Now
   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
Hide  View All  NextLaunch Portfolio Diagnostics

Price to Earning

Price to Earning Comparative Analysis
WAVE Life is currently under evaluation in price to earning category among related companies. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investor monitor on a daily basis. Holding a low PE stock is less risky because. When a company's profitability fall, it is likely that earnings will also go down..In other words, if you start from a lower position your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.